VYNE Therapeutics Inc. 8-K

What Happened
VYNE Therapeutics (VYNE) announced in an 8-K that Nasdaq notified the company it was non‑compliant with the $1.00 minimum closing bid requirement under Nasdaq Rule 5550(a)(2) after 30 consecutive business days below $1.00. The company missed the initial cure period ending March 10, 2026, but on March 11, 2026 Nasdaq granted a second 180‑calendar‑day extension, giving VYNE until September 7, 2026 to regain compliance.

Key Details

• Nasdaq granted a second compliance period of 180 calendar days; new deadline is September 7, 2026.
• To regain compliance, the bid price must close at or above $1.00 for at least 10 consecutive business days.
• Nasdaq noted VYNE meets the market value of publicly held shares and other initial listing requirements except the bid price.
• The company said it may consider options to cure the deficiency, including a reverse stock split; trading will continue on Nasdaq under the symbol “VYNE” for now.
• If compliance is not demonstrated by Sept 7, 2026, Nasdaq will notify VYNE of delisting, and VYNE could appeal to a Nasdaq Hearings Panel.

Why It Matters
This filing signals a continued risk that VYNE’s shares could be delisted if the stock price doesn’t recover or the company doesn’t take corrective action (e.g., reverse split). Delisting could reduce liquidity and make it harder for some investors to trade the stock. The extension preserves normal Nasdaq trading for now and gives investors a clear timeline (through Sept 7, 2026) to watch for price recovery or company actions to cure the deficiency.